Live Breaking News & Updates on Commercialization First Stage

News Category Global Banking & Finance Reviews
Genetic Technologies Provides Update on its COVID-19 Disease Severity Risk Test and Expansion into Germline Testing
Genetic Technologies Provides Update on its COVID-19 Disease Severity Risk Test and Expansion into Germline Testing
MELBOURNE, Australia, Jan. 21, 2021 Molecular diagnostics company Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”), provides the following update to the market on further development on the COVID-19 serious disease risk Polygenic Risk Score Test (COVID-19 PRS Test) and expansion of the Company’s offering to include Germline Testing division.
Key Highlights
Total COVID-19 positive patient data analyzed exceeds 5,500 following inclusion of further 4,000 patients’ data   º  Predictive capabilities improved 100% over age and sex alone ....

United States , United Kingdom , Stephanie Ottens , Laboratory Implementation , Medicaid Services Clinical Laboratory Improvement Amendments , Genetic Technologies Limited , Genetic Technologies Ltd , Exchange Commission , Centers For Medicare , Genetic Technologies , Company Genetype For Colorectal Cancer , Australian Genome Research , Company Genetype For Breast Cancer , Polygenic Risk Score Test , Germline Testing , Clinical Laboratory Improvement Amendments , Breast Cancer , Lynch Syndrome , Colorectal Cancer , Next Generation Sequencing Test , Commercialization First Stage , Testing Divisionexpanding , Technologies Limited , Results Release Date , Technologies Ltd , Note Regarding Forward Looking Statements Certain ,